|
Our New Pick Is…
Arch Therapeutics, Inc. (symbol: ARTH)
Hello Trader,
ARTH is currently experiencing strong upward momentum and offers an opportunity for potentially strong upside.
Before erupting for a 12-month high of .54 in early April, ARTH had undergone lengthy consolidation. The company is now set on a new paradigm and has been on an upward trajectory since the major breakout recorded on April 7.
ARTH is rated as a “Buy” on Barchart.com and is trading above both its 50 and 200 DMA. We believe that with the strong upward momentum there is a good deal of gains to be had before ARTH challenges its historical high.
The play is currently trading just under 40 cents and strong volatility levels suggest that momentum will continue, at least in the near term.
ARTH also has strong news, including an announcement confirming the receipt of a notice of allowance from the U.S. Patent Office. This news, along with the company’s upcoming participation at an investing conference, is helping to power interest in the play.
Entry at current levels is supported by solid liquidity so there’s no reason traders should miss out on this ongoing momentum opportunity.
Start your research now.
Website: http://www.archtherapeutics.com/
Technicals
Chart: http://www.barchart.com/interactive_charts/stocks/ARTH
ARTH has surpassed both its 50 and 200 DMAs. This is a huge momentum signal that confirms the play is in breakout territory.
ARTH is undervalued relative to its 12-month historical high and offers up to 38% upside opportunity over the near term.
ARTH is trading with a 54 RSI on the daily chart. This level suggests that the play is moving upward and could test higher overbought levels.
ARTH rallied to its 12-month high on April 7, rewarding traders on the day with up to 20% intraday gains.
ARTH has a “Buy’ rating from Barchart.com; this confirms the play is in breakout mode and could continue on its strong upward trajectory.
News
ARTH announced that it received a notice of allowance from the U.S. Patent Office for a broad method-of-use patent that covers systemically administering the Company's self-assembling technology for treating damaged extracellular matrix and leaky tight junctions.
Many disorders are associated with leakage around blood vessels and within the tight junctions between cells. Such leakage can lead to fluid invading the tissues, causing a loss in blood pressure, organ dysfunction or failure, and death. Some examples include inflammatory bowel disease, sepsis and ischemic stroke.
Dr. Terrence W. Norchi, President and CEO of Arch Therapeutics, said, "This important patent lends additional support to Arch's planned products. It is another example of Arch's inventiveness in exploring better ways to address a range of areas of unmet or poorly met medical needs with our self-assembling peptide technology."
Arch has filed its own patent applications and, in addition, has licensed worldwide exclusive rights to certain patents and patent applications assigned jointly to MIT and Versitech Limited, the technology transfer company of the University of Hong Kong, and worldwide non-exclusive rights to another portfolio of patents assigned jointly to MIT and Versitech Limited.
Medical Device Market To Reach $398 Billion By 2017
A new report by Visiongain predicts the global medical devices market will reach $398 billion in 2017. That industry generated $321 billion in 2012, and its revenues will show strong growth to 2023. That revenue forecast and others appear in Medical Devices Industry and Market Prospects 2013-2023. Visiongain is a business information provider based in London, UK.
The medical devices industry will witness significant opportunities for growth in the coming decade. Visiongain believes that market expansion will be driven by the introduction of innovative devices into the market and also by the demand generated by illnesses associated with the aging global population.
Cardiac and respiratory diseases generally affect people above the age of 65, and with the global over-65 population expected to rise up to 1 billion by 2020, devices used in the treatment of age-related illnesses will see significant growth in their revenues.
Research: http://www.otcmarkets.com/stock/ARTH/quote
ARTH has three major catalysts:
The company is currently in breakout mode and is experiencing rising daily volatility.
ARTH is rated highly by Barchart.com – currently a “buy.”
ARTH is poised to test its recently set historical 12 month high of .54.
Start your research on ARTH now.
Able Trader
|
